C-NBUCCambrian Bio
aging biology, mTORC1 inhibition, AMPK activation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-NBUC
C-NBUCC-NBUCaging biology, mTORC1 inhibition, AMPK activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cambrian Biopharma states that medicine should focus on understanding and treating the molecular and biochemical damage that accumulates in the body before it manifests as age-related disease. It argues that most drugs for age-related diseases treat symptoms rather than root causes, and that drugs targeting the hallmarks of aging could prevent or delay multiple major diseases while extending healthy lifespan, shifting therapeutics from "sickcare" to "healthcare."
SourceCambrian Biopharma states that healthcare in the 21st century will be redefined by medicines designed to lengthen healthspan, meaning the period of life spent in good health. It presents itself as pursuing this goal by combining breakthroughs in biomedicine with a rigorous, data-driven approach to building a therapeutic pipeline.
SourceNo substantive company mission, longevity thesis, or scientific belief is visible in the provided Wayback snapshot text. The only company-specific visible text appears to be the footer copyright notice and the call to action "Join our Team," which does not state a belief or theory.
SourceCambrian states that medicine should shift from reacting to individual diseases toward proactively extending healthy lifespan by addressing the biological root causes of age-related disease. It presents aging biology as a tractable therapeutic target, argues that drugs aimed at the hallmarks of aging could prevent or treat multiple major diseases, and says this should be pursued through a diversified, scientifically rigorous portfolio of early-stage therapeutics.
Source